Loxiglumide is a potent, orally active, and selective CCK-A receptor antagonist which stimulates calorie intake and hunger feelings in humans. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying. Intravenous administration of loxiglumide antagonized the CCK-induced reduction of gastric emptying in rats, acceleration of intestinal transport in mice, increase in ileal motility in rabbits, gallbladder contraction in guinea pigs and acceleration of gallbladder emptying in mice.

Xenthiorate was studied as an antihyperlipidemic agent. Information about the current use of this agent is not available.

Saviprazole (also known as HOE 731) is a potent inhibitor of gastric H+/K(+)-ATPase that has been studied in phase I clinical trial for the treatment of gastric ulcer. However, this study was discontinued.

Axitirome (also known as CGS 26214), a thyroid hormone receptor β selective agonist and an LDL receptor function stimulant, has a cholesterol-lowering activity. This drug was in phase I clinical trials for the treatment of hyperlipidemia, but studies were discontinued because of the unexpected side effects.

Nicofibrate is an antilipidemic drug. Treatment of diabetics led to a significant reduction in plasma cholesterol and triglycerides and brought the lipoprotein picture back within the norm. Nicofibrate did not lead to significant increases in uricaemia nor to any worsening in carbohydrate tolerance. Nicofibrate may also lead to a significant drop in plasma prothrombinic activity.

Fenaftic acid is a choleretic agent.

Pirinixil is an ethanolamine derivative of Wy-14,643 [4-chloro-6-(2,3-xylidino)-2-pyrimidinythio]acetic acid. It is the hypolipidemic agent of low toxicity. It has been reported to increase high density lipoprotein cholesterol levels in experimental animals. Pirinixil increased plasma cholesterol levels significantly without affecting plasma triglycerides. Pirinixil exerted a powerful antilipolytic activity against epinephrine, ACTH, nicotine and cold exposure. It is a potent inducer of liver peroxisones and of mitochondrial carmitine acetyltransferase. Pirinixil was developed treatment of hyperlipidemias and atherosclerosis. Pirinixil can increase generation of ROS, leading to DNA damage and p53 phosphorylation, which, in turn, induces the activation of Bax, release of cytochrome-c from mitochondria and activation of caspases, culminating in rat hepatoma FaO cell death.

Muraglitazar previously known as BMS-298585 has been identified as a non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor alpha/gamma. Muraglitazar is currently in clinical trial phase III development for the treatment of type 2 diabetes and dyslipidemia.

Spiroglumide (CR2194) is a potent and specific cholecystokinin-B (CCKB)/gastrin receptor antagonist structurally similar to lorglumide. Gastrin receptor blockade with CR2194 alters gastric acid secretion in response to food ingestion or to sham feeding. The results support a physiological role for gastrin in regulating acid secretion in humans. In healthy volunteers, intravenous infusion of spiroglumide was shown to reduce basal and postprandial intragastric acidity. These data also support the thesis that CCK2 receptor antagonism is an effective means to suppression gastric acid secretion. Although the oral bioavailability of spiroglumide was an improvement over L-365,260, it was not very potent and had little selectivity for the CCK2 receptor over the CCK1 receptor. These factors seem likely to have contributed to the decision not to continue its development

Feneritrol is a hypocholesteraemic agent.